Harry Meade serves as Executive at GTC BIOTHERAPEUTICS INC, where they oversee executive responsibilities. Since joining the company, Harry Meade has executed 10 insider transactions totaling $9.0K, demonstrating a bullish approach to their equity position. Their most recent transaction on Nov 2, 2009 involved receiving (via award) 13,598 shares valued at $16.5K.
Harry Meade currently holds 29,452 shares of GTC BIOTHERAPEUTICS INC (GTCB), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Harry Meade has been a net buyer of GTCB stock. They have purchased $9.0K and sold $0 worth of shares.
Harry Meade's most recent insider trade was on Nov 2, 2009, when they sold 13,598 shares at $1.21 per share.
Get notified when new Form 4 filings are submitted
| $1.21 |
| Discretionary |
| Nov 2, 2009 | GTCB | $6.7K | Payment | 5,520 | $1.21 | Discretionary |
| Jun 30, 2009 | GTCB | $3.1K | Payment | 1,165 | $2.66 | Discretionary |
| Jan 2, 2009 | GTCB | $0 | Award | 5,400 | $N/A | Discretionary |
| Jul 1, 2008 | GTCB | $0 | Award | 30,600 | $N/A | Discretionary |
| Mar 7, 2008 | GTCB | $0 | Award | 34,986 | $N/A | Discretionary |
| Dec 14, 2007 | GTCB | $9.0K | Purchase | 10,000 | $0.90 | Discretionary |
| Aug 10, 2006 | GTCB | $1.2K | Award | 1,000 | $1.23 | Discretionary |
| Mar 10, 2006 | GTCB | $0 | Award | 40,664 | $N/A | Discretionary |